Press coverage about Anthera Pharmaceuticals (NASDAQ:ANTH) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Anthera Pharmaceuticals earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.5327314964293 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

A number of brokerages have issued reports on ANTH. Zacks Investment Research raised Anthera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 25th. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Anthera Pharmaceuticals in a research note on Tuesday, September 19th. Finally, ValuEngine upgraded Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $5.11.

Anthera Pharmaceuticals (NASDAQ:ANTH) traded up $0.09 during trading on Friday, reaching $1.60. The company’s stock had a trading volume of 268,551 shares, compared to its average volume of 528,405. Anthera Pharmaceuticals has a 1 year low of $1.20 and a 1 year high of $17.04.

Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.32. During the same period in the prior year, the firm posted ($4.85) EPS. equities analysts anticipate that Anthera Pharmaceuticals will post -3.14 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was published by Daily Political and is the property of of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/12/10/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-anthera-pharmaceuticals-anth-stock-price.html.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Insider Buying and Selling by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.